Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 10 of 44

TitleReference numberPublishedLast updated
Cannabidiol with clobazam for treating seizures associated with Dravet syndromeTA614
Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndromeTA615
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumabTA612
Pentosan polysulfate sodium for treating bladder pain syndromeTA610
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal)TA608
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)TA609
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery diseaseTA607
Lanadelumab for preventing recurrent attacks of hereditary angioedemaTA606
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoeaTA605
Idelalisib for treating refractory follicular lymphomaTA604

Results per page

  1. 10
  2. 25
  3. 50
  4. All